What Limits Salicylic Acid Physical Stability in Veterinary Otic Drop Formulations?

Salicylic acid veterinary-grade API intended for otic drop manufacture is released against Ph. Eur. 0366 and USP Salicylic Acid with assay 99.0–101.0% on dried basis, melting range 158–161°C, sulfated ash ≤0.1%, and related substances controlled by liquid chromatography. The weak-acid pKa of 2.97 and aqueous solubility of approximately 2 g/L at 25°C define the formulation envelope. In a 0.5% w/v hydroalcoholic vehicle containing 20% v/v propylene glycol and 25% v/v ethanol, salicylic acid remains dissolved at pH 3.0 ± 0.2. Raising pH above 3.5 increases salicylate ionization and can reduce partitioning of free acid into ceruminous debris; lowering pH below 2.5 can precipitate free salicylic acid through common-ion effects in high-ethanol vehicles. Compliance for finished otic drops is governed by 21 CFR 210/211 current good manufacturing practice, USP <71> for sterile-labeled lots, USP <51> for preservative effectiveness, and Ph. Eur. 0366 for salicylic acid identity, infrared spectrophotometry, and HPLC assay. Manufacturing overage of 2.0% of label claim is typical to compensate for filtration and filling losses.

Production-scale processing in a 1000 L jacketed 316L stainless steel vessel with counter-rotating anchor agitation at 45–60 rpm begins with pre-sieving salicylic acid through a 500 µm screen. The powder is dissolved in the heated propylene glycol/ethanol fraction at 40 ± 2°C; the aqueous phase is added under vacuum with continuous agitation to avoid a transient cloud point. The cooled 20–25°C bulk is adjusted to pH 3.0 ± 0.2 with 1 M NaOH, then recirculated through a 0.45 µm capsule filter. On production lines, filter fouling occurs when the salicylic acid mass balance is overcharged by more than 2%: undissolved crystals blind the upstream filter face and the pressure differential exceeds 1.0 bar within 15 min. Filled bulk is packaged at fill-head temperature 20 ± 1°C to limit ethanol volatility and maintain label claim within 98.0–102.0%. The formulation envelope below is used for feasibility evaluation, not as a release specification.

Finished product type is a clear otic drop in 15 mL or 30 mL LDPE dropper bottles with tamper-evident closures. The indication is canine otitis externa or feline otic dermatitis when salicylic acid is used as a keratolytic and antimicrobial adjunct. Terminal labeling is either nonsterile multi-dose with preservative effectiveness data or sterile single-dose according to USP <71>.

In high-volume swine and cattle operations where medicated drinking water is the only practical mass-administration route, salicylic acid is converted to sodium salicylate in a dry effervescent granulation that must remain free-flowing at warehouse humidity and dissolve completely in hard water at low temperature. API acceptance for this route uses Ph. Eur. 0366 or USP Salicylic Acid with sulfated ash ≤0.1% and heavy metals ≤10 ppm; finished oral powders or granules are released under Regulation (EU) 2019/6 where authorized, with residual solvent and degradation-product control aligned with VICH GL18. Formulation addition ratio is 26.0% w/w salicylic acid, 40.0% w/w sodium bicarbonate, 18.0% w/w anhydrous citric acid, 14.5% w/w lactose monohydrate, 1.0% w/w povidone K30, and 0.5% w/w colloidal silicon dioxide. The salicylic acid-to-sodium bicarbonate stoichiometric neutralization ratio is 1.00:0.61 by mass; the remaining bicarbonate participates in citric acid effervescence. Reconstitution at 0.1% w/v targets pH 6.8–7.2 with no free salicylic acid precipitation for 24 h in water of 250 ppm CaCO3 hardness at 10°C.

Granulation is performed in a top-spray fluid bed with inlet air at 55–60°C, outlet air at 32–38°C, and binder spray rate 12–18 g/min per 500 kg batch. Lactose pre-drying at 80°C for 4 h is required when plant relative humidity exceeds 60%; otherwise the powder bridges in the oscillating hopper and mass flow stops. Final granulate moisture is controlled to <2.0% by Karl Fischer, with a sieve fraction of 100–800 µm and angle of repose below 35°. The finished type is a water-soluble granule or powder packed in 500 g or 1 kg foil-aluminum laminate pouches for direct in-line dosing into swine drinking water tanks or cattle proportioner systems.

When Injectable Sodium Salicylate Is Terminally Sterilized at 121°C

When injectable sodium salicylate is terminally sterilized at 121°C for 15 min, the critical variables are pH before autoclaving, headspace oxygen, and stopper moisture. A 10.0% w/v sodium salicylate parenteral for cattle and swine is manufactured from salicylic acid 8.6% w/v and sodium hydroxide 2.5% w/v in water for injection; sodium metabisulfite 0.1% w/v is added as antioxidant. pH is adjusted to 7.0 ± 0.2, and the solution is sparged with nitrogen to reduce dissolved oxygen below 1 ppm. Compliance requires Ph. Eur. 2.6.1 or USP <71> sterility, Ph. Eur. 2.6.14 or USP <85> bacterial endotoxins, USP <788> particulate matter for large-volume parenterals, and 21 CFR 210/211 aseptic processing controls.

Production is run in a Class C suite with Grade A laminar flow. Salicylic acid is charged into nitrogen-purged water for injection at 20–25°C; sodium hydroxide is injected below the liquid surface with high-shear mixing to avoid local pH above 9.0. Alkaline pH excursions accelerate oxidative degradation toward gentisic acid, visible as pale-yellow color drift and measurable by HPLC with a gentisic acid limit of ≤0.5% peak area. The bulk is filtered through a 0.22 µm PVDF membrane and filled into 100 mL Type I borosilicate vials with bromobutyl rubber stoppers under nitrogen. Terminal steam sterilization at 121°C for 15 min is acceptable only when pH is held at 6.8–7.2; pH values above 7.4 before autoclaving increase degradation to salicylaldehyde-related impurities. Batch-to-batch color drift typically traces to residual iron in the water loop or incomplete nitrogen purge rather than salicylic acid purity. Finished product type is a sterile, preservative-free 100 mL single-dose vial for intravenous or intramuscular administration in registered large-animal protocols.

Keratolytic ointment compounding for crusting and hyperkeratotic skin conditions in production animals uses salicylic acid at 2.0–10.0% w/w in a white soft paraffin/liquid paraffin base, with the lower end preferred for porcine exudative dermatitis and the upper end reserved for dense crust removal on cattle hocks. The monographed API is released under Ph. Eur. 0366 or USP Salicylic Acid; the semisolid finished product is tested according to Ph. Eur. 0132 for semisolid preparations and USP <795> if compounded as a nonsterile preparation. In an anhydrous base, salicylic acid remains largely undissolved; particle size therefore controls both efficacy and grittiness. The API is micronized through a 100 µm sieve before addition. The base is melted at 70 ± 2°C in a vacuum-jacketed mixer, cooled to 40°C under sweep agitation at 20–30 rpm, and the salicylic acid is dispersed with low-shear mixing to avoid aeration. The cooled mass is passed through a three-roll mill with gap setting 25–50 µm at 25°C to reduce agglomerates and improve content uniformity to 95–105% of label claim across top, middle, and bottom sampling ports.

Incompatibility is documented with zinc oxide or calamine in the same anhydrous base: salicylic acid reacts with divalent zinc to form zinc salicylate, producing a gritty texture and reducing free salicylic acid assay. Finished product is packed in 15 g, 30 g, or 250 g HDPE jars or laminated aluminum tubes. Aluminum tubes are preferred when the formulation contains no aqueous phase and long-term water-vapor transmission must remain below 0.1 g/m²/day to prevent base hardening.

Solid Oral Dosage Manufacture via In-Situ Neutralization Granulation

Solid oral dosage forms for companion animals and equine use can be manufactured from salicylic acid API by in-situ neutralization with sodium bicarbonate during wet granulation, producing sodium salicylate in the granulate rather than using a separate salt. The addition ratio is 55.7% w/w salicylic acid and 34.0% w/w sodium bicarbonate, a 1.00:0.61 mass ratio for stoichiometric conversion; microcrystalline cellulose 9.0% w/w, crospovidone 1.0% w/w, and magnesium stearate 0.3% w/w complete the core. The pre-blend is granulated in a high-shear granulator with impeller speed 150 rpm and chopper speed 1800 rpm using 5.0% w/w povidone K30 aqueous binder. End of granulation is judged by torque increase and visual dough formation at 30 ± 2°C. Wet mass is screened to 1.5 mm and dried in a fluid bed to <1.8% loss on drying.

Tablets are compressed on a 16-station rotary press with force 12–18 kN, resulting in hardness 80–120 N, friability <0.8%, and disintegration <15 min per USP <701>. Release testing also includes USP <711> dissolution and USP <905> uniformity of dosage units; cGMP compliance is under 21 CFR 210/211. Compression force above 18 kN has caused capping and lamination on production batches due to elastic recovery of the granulate, so the upper force limit is fixed. The finished types are 325 mg capsules filled with a dosator-type capsule machine or 750 mg tablets packed in HDPE bottles with desiccant canisters. Enteric coating may be required to reduce gastric irritation; published data for this specific veterinary indication is limited, and prescribing in the United States for non-approved species use is governed by AMDUCA.

Where a drinking-water premix is authorized in a target market, salicylic acid veterinary-grade API is formulated into a water-soluble powder for poultry or swine by blending 25.0% w/w salicylic acid, 40.0% w/w sodium bicarbonate, 18.0% w/w anhydrous citric acid, 16.0% w/w lactose monohydrate, 0.5% w/w polysorbate 80, and 0.5% w/w colloidal silicon dioxide. The salicylic acid-to-sodium bicarbonate mass ratio is 1.00:1.60, of which 1.00:0.61 neutralizes salicylic acid to sodium salicylate on dissolution and the remainder reacts with citric acid for effervescent dispersal. Blending is performed in a V-blender with intensifier bar for 15 min for a 250 kg batch under plant relative humidity <35%. Over-blending beyond 30 min causes segregation because salicylic acid, lactose, and citric acid have different bulk densities; assay variability across sampling ports then exceeds ±5.0% label claim. Powder is screened through an 800 µm in-line sifter and packed in 1 kg, 5 kg, and 25 kg foil-lined bags with heat-sealed closures.

Compliance for residual solvents, impurity control, and stability is aligned with VICH GL18 and Regulation (EU) 2019/6 if the product is registered for food-producing species; however, published data for this specific configuration is limited, and authorization status must be confirmed for the destination jurisdiction before quotation. Finished product type is a water-soluble premix that reconstitutes at 0.1% w/v to a pH 6.8–7.2 solution for proportional drinking-water medication systems.